

Optimal Dosage of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa

Hayley Sumich, BS¹; Nicholas Culotta, MD²

¹Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA

²Louisiana State University Health Sciences Center, Department of Dermatology, New Orleans, LA



Introduction

- Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatologic condition associated with painful lesions, nodules, sinus tracts, and scarring.¹
- Patients with HS exhibit lower levels of anti-inflammatory cytokines and increased levels of pro-inflammatory cytokines compared to unaffected individuals, making systemic inflammation a major aspect of the pathology of HS.¹
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of synthetic peptides that are used for their metabolic benefits, including increasing insulin production and suppressing appetite, ultimately leading to weight loss.¹
- Recent studies suggest that GLP-1 RAs may prove beneficial in the management of HS symptoms and disease progression. GLP-1 RAs inhibit pro-inflammatory cytokines, specifically TNF- α , which is an essential factor in the synthesis of many other pro-inflammatory cytokines. In doing so, GLP-1 RAs reduce the systemic inflammation associated with HS.¹
- Additionally, previous studies have suggested a connection between HS and obesity, further supporting the use of GLP-1 RAs for HS management.¹
- While semaglutide is the most commonly used GLP-1 RA for HS management, tirzepatide is currently being explored as another treatment option.
- There is currently no standardized dosing regimen for GLP-1 RAs in the treatment of HS, so our study intends to establish a suggested dosing regimen based on previous case reports and cohort studies

Methods

- We conducted a systematic review by searching databases, specifically PubMed and Google Scholar, without date limitations in search of articles that discussed the dosage of semaglutide and tirzepatide used for the treatment of HS. Key search terms included combinations of “GLP-1 RA”, “GLP-1 agonists”, “semaglutide”, “tirzepatide”, “hidradenitis suppurativa”, and “acne inversa”.

PRISMA Diagram




Figure 1. PRISMA Flow Diagram of report collection process⁷

Clinical Image



Figure 2. Hidradenitis suppurative of the axilla⁸

Results

- Semaglutide, when used in addition to other HS treatments, was effective in improving patient quality of life and reducing HS flares at doses as low as 0.8 ± 0.4 mg weekly, which is below the typical dose prescribed for obesity.²
- Evidence suggests reductions in HS symptoms increase with increased semaglutide dosage, with one study dosing up to 1.36 ± 0.86 mg weekly.⁴
- One case study reports the use of tirzepatide for HS treatment. The patient in this study received a dosage up to 7.5 mg/0.5 mL weekly and experienced significant improvement in HS symptoms, with her HS being reduced from moderate to mild over the course of 3 months.⁵
- When directly compared, tirzepatide was found to lead to greater weight loss (and possible alleviation of HS symptoms) than semaglutide, although tirzepatide had a higher risk (5-7%) of serious adverse effects compared to semaglutide (3%).⁶

Conclusion

- Semaglutide may be used at low doses (below 1 mg) in addition to other HS treatments for moderate success in HS treatment.
- Use of semaglutide at higher doses (above 1 mg) likely leads to greater HS symptom improvement.
- Additionally, tirzepatide provides promise for HS treatment and may be more effective than semaglutide, but more research must be done to establish an optimal dosage.

References:

1. Krajewski PK, Zlotowska A, Szepletowski JC. The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects. J Clin Med. 2024 Oct 22;13(21):6292. doi: 10.3390/jcm13216292. PMID: 39518431; PMCID: PMC11547001.
2. Daniel Lyons, Anusha Louly Nathan, Emily Pender, Gregg Murray, Conor Smith, Brian Kirby, Rosalind Hughes. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life, British Journal of Dermatology, Volume 191, Issue 4, October 2024, Pages 631–633, <https://doi.org/10.1093/bjd/ljac216>
3. Posada Posada MI, Alora MB, Lima XTV. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024 Oct 19. doi: 10.1111/jdv.20392. Epub ahead of print. PMID: 39425524.
4. Drumm, Claire Clowry, Julianne Healy, Marie-Louise Wynne, Bairbre et al. 42762 Successful treatment of hidradenitis suppurativa with semaglutide. Journal of the American Academy of Dermatology, Volume 89, Issue 3, AB89
5. Chan, Lina J. et al. A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide. JAAD Case Reports, Volume 52, 101 - 102
6. Frias, Juan P., et al. “Tirzepatide Versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” *New England Journal of Medicine*, Vol. 385, No. 6, 5 Aug. 2021, pp. 503–515, <https://doi.org/10.1056/nejmoa2107519>.
7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
8. James, W. D., Elston, D. M., Treat, J. R., Rosenbach, M. A., & Neuhaus, I. M. (2025). *Andrews' Diseases of the Skin: Clinical Dermatology* (14th ed.). Elsevier.